gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cancer/testis antigen 2

CT2, LAGE-1, CAMEL
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants. [provided by RefSeq, May 2010] (from NCBI)
Top mentioned proteins: Rab3D, HAD, cardiotrophin-1, CAN, AGE
Papers on CT2
Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty.
New
Nizzardo et al., Budapest, Hungary. In Br J Anaesth, Feb 2016
BACKGROUND: The aim was to evaluate the analgesic efficacy and safety of the dexketoprofen/tramadol 25 mg/75 mg fixed-dose combination vs dexketoprofen (25 mg) and tramadol (100 mg) in moderate-to-severe acute pain after total hip arthroplasty.
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
New
Loehrer et al., Indianapolis, United States. In Br J Cancer, Feb 2016
This work has led to the initiation of a phase II clinical trial of PI3K inhibition in relapsed or refractory thymomas (http://clinicaltrials.gov/ct2/show/NCT02220855).British Journal of Cancer advance online publication, 14 January 2016; doi:10.1038/bjc.2015.425
Predictors and Associations with Outcomes of Length of Hospital Stay in Patients with Acute Heart Failure: Results From VERITAS.
New
VERITAS Investigators et al., Durham, United States. In J Card Fail, Jan 2016
https://clinicaltrials.gov/ct2/results?term=NCT00525707&Search=Search.
Relationship between Age and Inappropriate Implantable Cardioverter Defibrillator Therapy in MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy).
New
Barsheshet et al., Tel Aviv-Yafo, Israel. In Heart Rhythm, Jan 2016
CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov/ct2/show/NCT00947310.
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
New
Mulders et al., Nijmegen, Netherlands. In Eur Urol, Jan 2016
identifier: NCT02002312 (https://clinicaltrials.gov/ct2/show/NCT02002312).
Text Messaging for Exercise Promotion in Older Adults From an Upper-Middle-Income Country: Randomized Controlled Trial.
New
Morris et al., Kuala Lumpur, Malaysia. In J Med Internet Res, Dec 2015
NCT02123342; http://clinicaltrials.gov/ct2/show/NCT02123342
A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial.
New
Molinari et al., Milano, Italy. In Trials, Dec 2015
https://clinicaltrials.gov/ct2/show/NCT02364505.
Culturally adaptive storytelling method to improve hypertension control in Vietnam - "We talk about our hypertension": study protocol for a feasibility cluster-randomized controlled trial.
New
Goldberg et al., Worcester, United States. In Trials, Dec 2015
REGISTRATION NUMBER: https://clinicaltrials.gov/ct2/show/NCT02483780 (registration date June 22, 2015).
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
New
Impact
June et al., Baltimore, United States. In Nat Med, Aug 2015
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1.
Development and Pilot Evaluation of a Tablet-Based Application to Improve Quality of Care in Child Mental Health Treatment.
Adams et al., Charleston, United States. In Jmir Res Protoc, 2014
OBJECTIVE: The aim of this study was to develop a scalable, sustainable technology-based approach to improve the quality of care in child mental health treatment.
The maize Gα gene COMPACT PLANT2 functions in CLAVATA signalling to control shoot meristem size.
Impact
Jackson et al., New York City, United States. In Nature, 2013
Here we show that maize COMPACT PLANT2 (CT2) encodes the predicted α-subunit (Gα) of a heterotrimeric GTP binding protein.
Potentially modifiable risk factors among veterans with spinal cord injury hospitalized for severe pressure ulcers: a descriptive study.
Review
Bombardier et al., United States. In J Spinal Cord Med, 2012
TRIAL REGISTRATION: http://clinicaltrials.gov/ct2/show/NCT00105859.
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
GeneRIF
Yee et al., Seattle, United States. In Plos One, 2011
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
GeneRIF
Zarour et al., Pittsburgh, United States. In J Immunol, 2011
Spontaneous LAGE-1-specific CD4-positive T cells isolated from patients with advanced LAGE-1-positive/NY-ESO-1-positive melanoma are directed against three promiscuous and immunodominant epitopes.
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
GeneRIF
Colleoni et al., São Paulo, Brazil. In Cancer Immun, 2010
LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis.
AIMing at metabolic syndrome. -Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM).-.
GeneRIF
Arai et al., Tokyo, Japan. In Circ J, 2010
AIM is involved in the progression of MetS in both an advancing and inhibitory fashion. Regulation of AIM could therefore be therapeutically applicable for MetS.
Anticytokine therapy in systemic lupus erythematosus.
Review
Yoo, Seoul, South Korea. In Lupus, 2010
We present the results mostly from published trials and data from http://clinicaltrials.gov/ct2/
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
GeneRIF
Boddy et al., Newcastle upon Tyne, United Kingdom. In Br J Cancer, 2010
Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.
Towards defining specific antigens for cutaneous lymphomas.
Review
Eichmüller, Heidelberg, Germany. In Onkologie, 2002
A growing list of tumor antigens can be summarized for CLs, especially CTCL, which include cTAGE-1, SCP-1, GBP-TA, several mimotopes, SC5, LAGE-1, and NY-ESO-1, as well as the GAGE and MAGE-A groups.
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.
Impact
Wiernik et al., Leipzig, Germany. In J Clin Oncol, 1998
Eight comparisons were designed to evaluate whether RT in a combined modality setting can be substituted by CT using either more cycles of the same CT or regimens that contain additional drugs (CT1 + CT2 v CT1 + RT or CT1 v CT2 + RT; parallel RT/CT design).
share on facebooktweetadd +1mail to friends